Salvizan gel for prevention of chemotherapy-induced oral mucositis: a randomised, double-blind, placebo-controlled trial

Key Points

• Salvizan gel significantly reduces the incidence of oral mucositis during chemotherapy treatment, improving patient comfort.
• In the trial, 35% of patients receiving the gel reported lower levels of mucositis compared to the placebo group.
• Randomised double-blind placebo-controlled trial assessed the impact of salvizan gel on oral mucositis across multiple treatment centers.
• These findings highlight the need for effective interventions against chemotherapy-induced side effects, improving the quality of life.